Caripill Tablets: Each tablet contains Carica Papaya Leaf Extract 1100 mg. Caripill Syrup: Each 5 ml contains Carica Papaya Leaf Extract 275 mg.

Caripill Tablets and Syrup contain Carica Papaya Leaf Extract, a standardized herbal formulation used as an adjunctive therapy to support platelet production in patients with thrombocytopenia. It is indicated for dengue-associated thrombocytopenia, chemotherapy-induced thrombocytopenia, and thrombocytopenia requiring treatment or prevention of bleeding. Clinical evidence suggests that Carica papaya leaf extract supports platelet production by enhancing the expression of genes involved in thrombopoiesis.

Caripill Tablets and Syrup are indicated as an adjunct for increasing thrombocyte (platelet) counts associated with dengue fever, for the treatment and/or prevention of bleeding in thrombocytopenia, and for chemotherapy-induced thrombocytopenia.

Carica Papaya Leaf Extract has been shown in clinical studies to enhance platelet production by upregulating genes involved in thrombopoiesis. Clinical evidence demonstrates an approximately 15-fold increase in ALOX12 gene activity and a 13.42-fold increase in PTFAR gene activity, both of which play important roles in platelet production. This mechanism contributes to improving platelet counts in patients with thrombocytopenia.

For Chemotherapy-Induced Thrombocytopenia: 1100 mg three times daily throughout the chemotherapy cycle. For Dengue: 1100 mg three times daily for 5 days. Children aged 1–5 years: 5 ml three times daily for 5 days. Children aged 6–12 years: 10 ml three times daily for 5 days, or as directed by the physician.

Caripill Tablets and Syrup are contraindicated in patients with known hypersensitivity to Carica Papaya Leaf Extract or any component of the formulation. They are also contraindicated during pregnancy due to insufficient safety data and in patients with disorders related to the prostate gland or benign prostatic hyperplasia (BPH).